Skip to main content

Advertisement

SpringerLink
Log in

How do I treat and follow my TUNA patients

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Transurethral needle ablation (TUNA) of the prostate is an alternative treatment for benign prostatic hyperplasia (BPH) generating temperatures around 100°C leading to necrotic lesions inside the prostate. TUNA is a minimally invasive, low morbidity associated, approach that uses radiofrequency energy. The needles are covered by teflon shields that protect the urethra from thermal injury. Since the introduction of TUNA, there has been a constant upgrading of the device to improve treatment quality. The main advantage of this therapy is the possibility of an outpatient care due to its anaesthesia-free option with a prostatic block. Catheterisation after the procedure is required in 10–40% of cases. Long-term data (5 years) on TUNA demonstrate a sustained improvement of both IPSS score and urinary flow. About a quarter of patients require further intervention at 5 years’ follow-up. The safety profile, along with the significant improvement in both objective and subjective parameters observed after TUNA, makes it an attractive approach for symptomatic BPH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Aho TF, Gilling PJ (2003) Laser therapy for benign prostatic hyperplasia: a review of recent developments. Curr Opin Urol 13(1):39–44

    Article  PubMed  Google Scholar 

  2. Anderson JT, Nickel JC, Marshall VR, Schulman CC, Boyle P (1997) Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 49:839

    Article  Google Scholar 

  3. AUA Practice Guidelines Committee (2003) AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1 diagnosis and treatment recommendations. J Urol 170:530

    Google Scholar 

  4. Blute ML, Larson T (2001) Minimally invasive therapies for benign prostatic hyperplasia. Urol Suppl 58:33

    Article  CAS  Google Scholar 

  5. Boyle P, Gould L, Roehrborn C (1996) Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride. A meta-analysis of randomized clinical trials. Urology 48:398–405

    Article  PubMed  CAS  Google Scholar 

  6. Boyle P, Robertson C, Lowe F, Roehrborn C (2000) Meta-analysis of clinical trials of Permixon in the treatment of BPH. Urology 55:533–539

    Article  PubMed  CAS  Google Scholar 

  7. Boyle P, Robertson C, Manski R, Padley RJ, Roehrborn CG (2001) Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 58:717–722

    Article  PubMed  CAS  Google Scholar 

  8. Bruskewitz R, Issa MM, Roehrborn C et al (1998) A prospective, randomised one-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 159:1588–1594

    Article  PubMed  CAS  Google Scholar 

  9. Campo B, Bergamaschi F, Corrada P et al (1997) Transurethral needle ablation (TUNA) of prostate: a clinical and urodynamic evaluation. Urology 49:847–850

    Article  PubMed  CAS  Google Scholar 

  10. Campo B, Muto G, Rigatti P et al (1995) TUNA: clinical reliability of a new procedure for prostatic obstruction treatment. J Urol 153:A1220

    Article  Google Scholar 

  11. Harewood LM, Cleeve KL, O’Connell HE et al (1995) Transurethral needle ablation of prostate (TUNA): clinical results and ultrasound, endoscopic, and histologic findings in pilot study of patients in urinary retention. J Endourol 9:407–412

    Article  PubMed  CAS  Google Scholar 

  12. Harewood LM, Cleeve LK, O’Connell HE, Pope AJ, Vaughan MG (1994) Transurethral Needle Ablation of the prostate (TUNA): a pilot study in patients in acute retention. J Endourol 8:A17–389

    Google Scholar 

  13. Hill B, Belville W, Bruskewitz R, Issa M, Perez-Marrero R, Roehrborn C, Terris M, Naslund M (2004) Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol 171(6 Pt 1):2336–2340

    Article  PubMed  Google Scholar 

  14. Kirby RS, Altwein JE, Bartsch G et al (2003) The efficacy and tolerability of doxazosin and finasteride, alone or in combination, in the treatment of symptomatic benign prostatic hyperplasia. results of the prospective European Doxazosin and combination therapy (PREDICT) trial. Urology 61:119–126

    Article  PubMed  Google Scholar 

  15. Lukacs B, Grange JC, Comet D, McCarthy C (1998) Three year prospective study of 3228 clinical BPH patients treated with alfuzosin in general practice. Prostate Cancer Prostatic Dis 1:276

    Article  PubMed  CAS  Google Scholar 

  16. Lukacs B, Leplege A, Thibault P, Jardin A (1996) Prospective study of men with clinical benign prostate hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology 48:731

    Article  PubMed  CAS  Google Scholar 

  17. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387–2398

    Article  PubMed  CAS  Google Scholar 

  18. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387

    Article  PubMed  CAS  Google Scholar 

  19. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. (1989) Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 141:243–247

    PubMed  CAS  Google Scholar 

  20. Naslund MJ, Benson RC, Cohen ES, Gutierrez-Aceves J, Issa MM (2000) Transurethral needle ablation (TUNA) for BPH in patients with median lobe enlargement. Report of a prospective multi-centre study. AUA Annual Meeting Clinical Abstracts. Williams & Wilkins/Lippincott, Baltimore/Philadelphia

  21. Naslund MJ, Carlson AM, Williams MJ (2005) A cost comparision of medical management and transurethral needle ablation for the treatment of benign prostatic hyperplasia during 5-year period. J Urol 173:2090–2093

    Article  PubMed  CAS  Google Scholar 

  22. Plentka L, Loghem JV, Hahn E et al (1991) Comorbidities and perioperative complications among patients with surgically treated benign prostatic hyperplasia. Urology 38(Suppl 1):43

    Article  Google Scholar 

  23. Ragavan N, Philip J, Balasubramanian SP, Desouza J, Marr C, Javle P (2005) A randomized, controlled trial comparing lidocaine periprostatic nerve block, diclofenac suppository and both for transrectal ultrasound guided biopsy of prostate. J Urol 174(2):510–513

    Article  PubMed  CAS  Google Scholar 

  24. Ramon J, Lynch TH, Eardley I et al (1997) Transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia: a collaborative multicentre study. Br J Urol 80:128–134

    PubMed  CAS  Google Scholar 

  25. Rasor JS, Zlotta AR, Edwards SD, Schulman CC (1993) Transurethral needle ablation: gradient mapping and comparision of lesion size in a tissue model and in patients with benign prostatic hyperplasia. Eur Urol 24:411–414

    PubMed  CAS  Google Scholar 

  26. Roehrborn C, Boyle P, Nickel J, Hoefner K, Andriole G (2002) Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60:434

    Article  PubMed  Google Scholar 

  27. Schulman CC, Zlotta AR (1995) Transurethral needle ablation of the prostate for treatment of benign prostatic hyperplasia: early clinical experience. Urology. 45(1):28–33

    Article  PubMed  CAS  Google Scholar 

  28. Schulman CC, Zlotta AR (1995) TUNA: a promising new therapy for BPH. Contemp Urol 7(10):59–60, 62, 64

    Google Scholar 

  29. Steele GS, Sleep DJ (1997) Transurethral needle ablation of the prostate: a urodynamic based study with 2-year followup. J Urol 158(5):1834–1838

    Article  PubMed  CAS  Google Scholar 

  30. Vaughan ED Jr (2003) Medical management of benign prostatic hyperplasia—are two drugs better than one? N Engl J Med 349:2449

    Article  PubMed  Google Scholar 

  31. Zlotta AR, Djavan B (2002) Minimally invasive therapies for benign prostatic hyperplasia in the new millennium: long-term data. Curr Opin Urol 12:7–14

    Article  PubMed  Google Scholar 

  32. Zlotta AR, Giannakopoulos X, Maehlum O, Ostrem T, Schulman CC (2003) Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for the treatment of symptomatic benign prostatic hyperplasia: Clinical outcome up to five years from three centers. Eur Urol 44:89–93

    Article  PubMed  Google Scholar 

  33. Zlotta AR, Peny MO, Matos C, Schulman CC (1996) Transurethral needle ablation of the prostate: clinical experience in patients in urinary acute retention. Br J Urol 77(3):391–397

    PubMed  CAS  Google Scholar 

  34. Zlotta AR, Schulman CC (1999) Interstitial maser coagulation for the treatment of benign prostatic hyperplasia using local anaesthesia only. BJU Int 83(3):341–342

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Erasme Hospital, Brussels University Clinics, 808 route de Lennik, 1070, Brussels, Belgium

    Sas Barmoshe & Alexandre R. Zlotta

Authors
  1. Sas Barmoshe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexandre R. Zlotta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandre R. Zlotta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barmoshe, S., Zlotta, A.R. How do I treat and follow my TUNA patients. World J Urol 24, 397–404 (2006). https://doi.org/10.1007/s00345-006-0091-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-006-0091-1

Keywords

Search

Navigation